NEENAH, WI, (GLOBE NEWSWIRE) — Plexus Corp. (NASDAQ: PLXS) today announced financial results for our fiscal first quarter ended December 28, 2024, and guidance for our fiscal second quarter ending March 29, 2025.
- Reports fiscal first quarter 2025 revenue of $976 million, GAAP operating margin of 4.8% and GAAP diluted EPS of $1.34.
- Reports fiscal first quarter 2025 non-GAAP operating margin of 6.0% and non-GAAP diluted EPS of $1.73, excluding $0.24 of stock-based compensation expense and $0.15 of restructuring and other charges, net of tax.
- Initiates fiscal second quarter 2025 revenue guidance of $960 million to $1.00 billion with GAAP diluted EPS of $1.22 to $1.37, including $0.24 of stock-based compensation expense. Fiscal second quarter non-GAAP EPS guidance of $1.46 to $1.61 excludes stock-based compensation expense.
| Three Months Ended | ||||||
| Dec 28, 2024 | Dec 28, 2024 | Mar 29, 2025 | ||||
| Q1F25 Results | Q1F25 Guidance | Q2F25 Guidance | ||||
| Summary GAAP Items | ||||||
| Revenue (in millions) | $976 | $960 to $1,000 | $960 to $1,000 | |||
| Operating margin | 4.8 | % | 4.9% to 5.3% | 4.6% to 5.0% | ||
| Diluted EPS | $1.34 | $1.25 to $1.40 | $1.22 to $1.37 | |||
| Summary Non-GAAP Items (1) | ||||||
| Adjusted operating margin (2) | 6.0 | % | 5.7% to 6.1% | 5.3% to 5.7% | ||
| Adjusted EPS (3) | $1.73 | $1.52 to $1.67 | $1.46 to $1.61 | |||
| Return on invested capital (ROIC) | 13.8 | % | ||||
| Economic return | 4.9 | % | ||||
| (1) | Refer to Non-GAAP Supplemental Information tables for additional information regarding non-GAAP financial measures. |
| (2) | Excludes stock-based compensation expense of approximately 70 bps for Q1F25 results, 50 bps for Q1F25 guidance and 70 bps for Q2F25 guidance. Excludes restructuring charges of approximately 50 bps for Q1F25 results and 30 bps for Q1F25 guidance. |
| (3) | Excludes stock-based compensation expense, net of tax, of $0.24 for Q1F25 results, $0.19 for Q1F25 guidance and $0.24 for Q2F25 guidance. Excludes restructuring charges, net of tax, of $0.15 for Q1F25 results and $0.08 for Q1F25 guidance. |
Fiscal First Quarter 2025 Information
- Won 30 manufacturing programs during the quarter representing $212 million in annualized revenue when fully ramped into production.
- Generated fiscal first quarter free cash flow of $27 million.
- Purchased $12.8 million of our shares at an average price of $151.19 per share under our 2025 Share Repurchase Program, leaving $37.2 million available under our existing $50.0 million authorization.
Todd Kelsey, President and Chief Executive Officer, commented, “Our team’s agility and responsiveness enabled strong operating performance in the fiscal first quarter, resulting in robust financial results to begin fiscal 2025. We delivered fiscal first quarter revenue of $976 million, in-line with expectations, and non-GAAP operating margin of 6.0%, near the high end of our guidance and consistent with our long-term goal. This contributed to non-GAAP EPS of $1.73, which exceeded guidance. Furthermore, free cash flow generation surpassed expectations, benefiting from the ongoing efforts of our fiscal 2024 initiatives to drive sustained improvement in working capital efficiency.”
Patrick Jermain, Executive Vice President and Chief Financial Officer, commented, “Aided by a cash cycle of 68 days, 5 days favorable to expectations, we delivered our best fiscal first quarter free cash flow performance in five years, generating $27 million. The ongoing improvements in our cash cycle also continue to benefit return on invested capital, which was 13.8% for the fiscal first quarter, or 490 basis points above our weighted average cost of capital. Although net working capital investments in support of program ramps are anticipated for the fiscal second quarter, our robust fiscal first quarter free cash generation positions us to now deliver up to $100 million of free cash for fiscal 2025. Finally, reinforcing our commitment to create additional shareholder value, we reduced our borrowing by $37 million and repurchased $13 million of our shares during the fiscal first quarter.”
Mr. Kelsey continued, “We delivered 30 fiscal first quarter manufacturing wins, representing $212 million in annualized revenue. The wins performance reflects continued strong contribution within our Healthcare/Life Sciences market sector as well as exciting growth opportunities within our Aerospace/Defense and Industrial market sectors. In addition, our engineering solutions team delivered a win total that approached a two-year high, while our funnel of engineering opportunities continues to see increased diversification. We believe both are strong leading indicators of future Plexus revenue growth.”
Mr. Kelsey concluded, “Considering current market sector dynamics and typical seasonal cost pressures, we are guiding to fiscal second quarter revenue of $960 million to $1.00 billion, non-GAAP operating margin of 5.3% to 5.7% and non-GAAP EPS of $1.46 to $1.61. Lastly, we remain confident in achieving meaningful EPS growth in fiscal 2025 by leveraging revenue expansion in each of our market sectors, ongoing strong operating margin performance and continued deployment of our free cash flow to create additional shareholder value.”
| Quarterly Comparison | Three Months Ended | ||||||||||
| (in thousands, except EPS) | Dec 28, 2024 | Sep 28, 2024 | Dec 30, 2023 | ||||||||
| Revenue | $ | 976,122 | $ | 1,050,569 | $ | 982,607 | |||||
| Gross profit | 100,692 | 107,912 | 88,140 | ||||||||
| Operating income | 46,860 | 53,858 | 45,158 | ||||||||
| Net income | 37,267 | 41,221 | 29,215 | ||||||||
| Diluted EPS | $ | 1.34 | $ | 1.48 | $ | 1.04 | |||||
| Gross margin | 10.3 | % | 10.3 | % | 9.0 | % | |||||
| Operating margin | 4.8 | % | 5.1 | % | 4.6 | % | |||||
| ROIC (1) | 13.8 | % | 11.8 | % | 10.3 | % | |||||
| Economic return (1) | 4.9 | % | 3.6 | % | 2.1 | % | |||||
| (1) | Refer to Non-GAAP Supplemental Information tables for non-GAAP financial measures discussed and/or disclosed in this release, such as adjusted operating margin, adjusted net income, adjusted diluted EPS, ROIC and economic return. |
Business Segment and Market Sector Revenue
Plexus measures operational performance and allocates resources on a geographic segment basis. Plexus also reports revenue based on the market sector breakout set forth in the table below, which reflects Plexus’ market sector focused strategy. Top 10 customers comprised 51% of revenue during the first quarter of fiscal 2025. This is down 1 percentage point from the fourth quarter of fiscal 2024 and up 3 percentage points from the first quarter of fiscal 2024.
| Business Segments ($ in millions) | Three Months Ended | |||||||||||
| Dec 28, 2024 | Sep 28, 2024 | Dec 30, 2023 | ||||||||||
| Americas | $ | 274 | $ | 307 | $ | 310 | ||||||
| Asia-Pacific | 607 | 618 | 553 | |||||||||
| Europe, Middle East and Africa | 101 | 128 | 121 | |||||||||
| Elimination of inter-segment sales | (6 | ) | (2 | ) | (1 | ) | ||||||
| Total Revenue (1) | $ | 976 | $ | 1,051 | $ | 983 | ||||||
| (1) | In the first quarter of fiscal 2025, Plexus changed its internal management reporting to focus on value-add sales in each region and adjusted the allocation of certain corporate costs amongst reportable segments. These changes have been implemented and are consistent with what is provided to the Chief Executive Officer as our chief operating decision maker. The Company’s composition of operating segments and reportable segments did not change. Net sales and operating income for our three reportable segments for the current period and comparative periods presented have been recast to conform to those changes. These changes had no effect on the Company’s consolidated net sales, operating income or net income for the current or comparative periods. Refer to the Supplemental Segment Information in Table 3 for the prospective presentation of previously filed periods. |
| Market Sectors ($ in millions) | Three Months Ended | |||||||||||||
| Dec 28, 2024 | Sep 28, 2024 | Dec 30, 2023 | ||||||||||||
| Aerospace/Defense | $ | 160 | 16 | % | $ | 184 | 18 | % | $ | 167 | 17 | % | ||
| Healthcare/Life Sciences | 374 | 38 | % | 415 | 39 | % | 381 | 39 | % | |||||
| Industrial | 442 | 46 | % | 452 | 43 | % | 435 | 44 | % | |||||
| Total Revenue | $ | 976 | $ | 1,051 | $ | 983 | ||||||||
